U.S. License Holder:
Wyeth Pharms. Inc.
Date of License:
August-17-2017
Last Update:
Nov-30-2023
FDA-Approved Indications
BESPONSA (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC) indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).